arrow
H

Hannah M. Cheeseman

technology and medicine
H指数:19
被引数:1,677

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial

HIV-1包膜三聚体疫苗诱导性别相关的抗体反应差异:一项1期临床试验

2025-11-210
OAAI
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth

使用稳定类天然HIV-1 Env免疫原的实验医学研究能够驱动长期抗体应答,但缺乏广谱中和能力。

2025-02-010
OAAI
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, doubleblind trial
2024-08-016
OAAI
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens
2023-07-133
OAAI
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

SARS-CoV-2自扩增RNA疫苗的COVAC1 2a期扩大安全性和免疫原性研究

2023-02-0118
OAAI
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

抗新型冠状病毒肺炎自我扩增RNA疫苗的安全性和免疫原性: COVAC1,I期剂量范围试验

2022-02-0194
OAAI
SARS- CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study
2021-03-0242
OAAI
Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey
THORAX
IF7.7
2020-08-1288
OAAI
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

以CAF01脂质体或氢氧化铝为佐剂的衣原体疫苗候选CTH522的安全性和免疫原性: 首次在人类,随机,双盲,安慰剂对照,1期试验

2019-10-01141
PREAI
Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV-1 Vaccine Candidates
2010-03-0170
PREAI